AUPH Aurinia Pharmaceuticals Inc.
Q3 2025 10-Q
Aurinia Pharmaceuticals Inc. (AUPH) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New U.S. national security investigation on pharmaceutical imports may trigger tariffs or trade restrictions impacting supply chain from Switzerland
- • Updated risk: potential retaliatory tariffs from Otsuka Territories on U.S. pharmaceutical imports could harm Otsuka's voclosporin sales and Aurinia's revenue
Quarterly Financial SummaryXBRL
Revenue
$73M
▲ +8.4% YoY▲ +4.9% QoQ
Net Income
$32M
▲ +119.9% YoY▲ +46.7% QoQ
Operating Margin
40.5%
▲ +2315bp YoY▲ +1180bp QoQ
Net Margin
42.9%
▲ +2177bp YoY▲ +1222bp QoQ
ROE
8.6%
Total Assets
$528M
EPS (Diluted)
$0.23
▲ +130.0% YoY▲ +43.8% QoQ
Operating Cash Flow
$44M
▲ +161.0% YoY▲ +0.5% QoQ
Source: XBRL data from Aurinia Pharmaceuticals Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Aurinia Pharmaceuticals Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.